Hutchmed (HCM) analyst forecast and price target
Analyst forecast
Consensus of 26 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Goldman Sachs | Maintained | Neutral | $14.00 from $16.00 | Jul 23, 2026 |
| B of A Securities | Maintained | Buy | $17.00 from $20.00 | Jul 7, 2026 |
| B of A Securities | Maintained | Buy | $20.00 from $21.00 | Mar 10, 2026 |
| Morgan Stanley | Downgraded | Equal-Weight → Underweight | $13.75 from $18.00 | Sep 22, 2025 |
| B of A Securities | Maintained | Buy | $28.00 from $27.00 | Jul 22, 2025 |
| Goldman Sachs | Maintained | Neutral | $19.00 from $17.00 | Aug 1, 2024 |
| Deutsche Bank | Upgraded | Hold → Buy | $22.10 from $20.00 | Nov 24, 2023 |
| Goldman Sachs | Maintained | Neutral | $17.00 from $15.00 | Nov 10, 2023 |
| Cantor Fitzgerald | Maintained | Overweight | $50.00 | Sep 5, 2023 |
| Cantor Fitzgerald | Maintained | Overweight | $50.00 | Jul 24, 2023 |
Frequently asked questions
Is HCM a buy, sell, or hold?
Analysts covering Hutchmed currently average a Buy rating: 21 buy, 5 hold and 0 sell, from 26 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on HCM?
On Jul 23, 2026, Goldman Sachs maintained Hutchmed at Neutral with a price target of $14.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.